OncoMatch/Clinical Trials/NCT06959641
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Is NCT06959641 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Zanzalintinib for locally advanced differentiated thyroid gland carcinoma.
Treatment: Zanzalintinib — This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). XL092 is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Thyroid Gland Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: xl092 (zanzalintinib) (xl092)
Cannot have received: small molecule kinase inhibitor
Cannot have received: cytotoxic, biologic, or other systemic anticancer therapy
Exception: rai, a radionuclide therapy given systemically, is allowed prior therapy
Lab requirements
Blood counts
leukocytes (wbc) ≥ 3,000/mcl, anc ≥ 1,500/mcl, hemoglobin (hgb) ≥ 9 g/dl, platelets (plt) ≥ 100,000/mcl
Kidney function
creatinine clearance (crcl) ≥ 40 ml/min (≥ 0.67 ml/sec) using the cockcroft-gault equation
Liver function
total bilirubin ≤ 1.5 x uln; for subjects with gilbert's disease ≤ 3 x uln, ast ≤ 3 x uln, alt ≤ 3 x uln, alp ≤ 3 x uln; for subjects with documented bone metastasis, ≤ 5 x uln
Cardiac function
corrected qt interval calculated by the fridericia formula (qtcf) ≤ 480 ms within 14 days per ecg before first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Harbor-UCLA Medical Center · Torrance, California
- Northwestern University · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06959641 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior xl092 (zanzalintinib), small molecule kinase inhibitor, cytotoxic, biologic, or other systemic anticancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages